Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Chronic conditions

Doctors call for improvement of inflammatory bowel disease services

The UK inflammatory bowel disease (IBD) audit was carried out by the Royal College of Physicians

Source: Justinc / Wikimedia Commons

The Royal College of Physicians carried out the UK IBD audit on behalf of the Healthcare Quality Improvement Partnership

Doctors are calling for a national strategy for inflammatory bowel disease (IBD) so that it receives the same attention as other chronic conditions such as diabetes.

The appeal follows publication of the latest UK IBD audit carried out by the Royal College of Physicians and commissioned by the Healthcare Quality Improvement Partnership — a consortium that promotes the use and results of clinical audit to improve the quality of health services.

The latest audit, covering the period from 2012 to 2014, found that IBD services varied. Around 86% of gastroenterology sites had specialist IBD nurses, up from 56% when the first UK audit of IBD services was carried out between 2006 and 2008. But only 37% of audited sites met the IBD standard of 1.5 whole time equivalent specialist nurses.

Although the number of IBD multidisciplinary team meetings increased from 75% in 2010-2012 to 91% in 2012-2014, only 40% met the preferred IBD standard by occurring every fortnight and involving medical, nursing and surgery staff.

Commenting on the audit, Anja St Clair Jones, the Royal Pharmaceutical Society’s spokeswoman for gastrointestinal medicine, highlights that there has been a modest improvement, with 59% of IBD multi-disciplinary teams (MDT) having a named pharmacist. “But only 16% of MDT meetings are attended by a pharmacist,” she adds.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066703

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £43.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.